170 related articles for article (PubMed ID: 19107232)
1. Oncogenic activation of MAP kinase by BRAF pseudogene in thyroid tumors.
Zou M; Baitei EY; Alzahrani AS; Al-Mohanna F; Farid NR; Meyer B; Shi Y
Neoplasia; 2009 Jan; 11(1):57-65. PubMed ID: 19107232
[TBL] [Abstract][Full Text] [Related]
2. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y
J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
[TBL] [Abstract][Full Text] [Related]
3. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene.
Lin JD; Fu SS; Chen JY; Lee CH; Chau WK; Cheng CW; Wang YH; Lin YF; Fang WF; Tang KT
Thyroid; 2016 May; 26(5):691-704. PubMed ID: 26914762
[TBL] [Abstract][Full Text] [Related]
4. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
5. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
[TBL] [Abstract][Full Text] [Related]
6. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
7. Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations.
Barollo S; Pezzani R; Cristiani A; Redaelli M; Zambonin L; Rubin B; Bertazza L; Zane M; Mucignat-Caretta C; Bulfone A; Pennelli G; Casal Ide E; Pelizzo MR; Mantero F; Moro S; Mian C
Thyroid; 2014 May; 24(5):809-19. PubMed ID: 24295088
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis.
Oler G; Camacho CP; Hojaij FC; Michaluart P; Riggins GJ; Cerutti JM
Clin Cancer Res; 2008 Aug; 14(15):4735-42. PubMed ID: 18676742
[TBL] [Abstract][Full Text] [Related]
9. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
Kondo T; Nakazawa T; Murata S; Kurebayashi J; Ezzat S; Asa SL; Katoh R
Hum Pathol; 2007 Dec; 38(12):1810-8. PubMed ID: 17714762
[TBL] [Abstract][Full Text] [Related]
10. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.
Puxeddu E; Moretti S; Elisei R; Romei C; Pascucci R; Martinelli M; Marino C; Avenia N; Rossi ED; Fadda G; Cavaliere A; Ribacchi R; Falorni A; Pontecorvi A; Pacini F; Pinchera A; Santeusanio F
J Clin Endocrinol Metab; 2004 May; 89(5):2414-20. PubMed ID: 15126572
[TBL] [Abstract][Full Text] [Related]
11. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status.
Paskaš S; Janković J; Marečko I; Išić Denčić T; Tatić S; Cvejić D; Savin S
Otolaryngol Head Neck Surg; 2014 Feb; 150(2):201-9. PubMed ID: 24255086
[TBL] [Abstract][Full Text] [Related]
12. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
[TBL] [Abstract][Full Text] [Related]
13. Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
Musholt PB; Musholt TJ; Morgenstern SC; Worm K; Sheu SY; Schmid KW
World J Surg; 2008 May; 32(5):722-8. PubMed ID: 18235983
[TBL] [Abstract][Full Text] [Related]
14. ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V600E) mutation compared to that of corresponding normal thyroid tissues.
Kim SW; Kim HK; Lee JI; Jang HW; Choe JH; Kim JH; Kim JS; Hur KY; Kim JH; Chung JH
Endocr Res; 2013; 38(2):89-97. PubMed ID: 23544999
[TBL] [Abstract][Full Text] [Related]
15. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
[TBL] [Abstract][Full Text] [Related]
16. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
17. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.
Melillo RM; Castellone MD; Guarino V; De Falco V; Cirafici AM; Salvatore G; Caiazzo F; Basolo F; Giannini R; Kruhoffer M; Orntoft T; Fusco A; Santoro M
J Clin Invest; 2005 Apr; 115(4):1068-81. PubMed ID: 15761501
[TBL] [Abstract][Full Text] [Related]
18. BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma.
Rusinek D; Swierniak M; Chmielik E; Kowal M; Kowalska M; Cyplinska R; Czarniecka A; Piglowski W; Korfanty J; Chekan M; Krajewska J; Szpak-Ulczok S; Jarzab M; Widlak W; Jarzab B
PLoS One; 2015; 10(12):e0143688. PubMed ID: 26625260
[TBL] [Abstract][Full Text] [Related]
19. High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas.
de Biase D; Cesari V; Visani M; Casadei GP; Cremonini N; Gandolfi G; Sancisi V; Ragazzi M; Pession A; Ciarrocchi A; Tallini G
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1530-8. PubMed ID: 24780046
[TBL] [Abstract][Full Text] [Related]
20. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
Mitsiades CS; Negri J; McMullan C; McMillin DW; Sozopoulos E; Fanourakis G; Voutsinas G; Tseleni-Balafouta S; Poulaki V; Batt D; Mitsiades N
Mol Cancer Ther; 2007 Mar; 6(3):1070-8. PubMed ID: 17363500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]